Table 1.
Characteristics of the IPF and control cohorts
| Characteristic | IPF (N = 300) | Control (N = 100) |
|---|---|---|
| Age (years) | 70.0 (65.0, 75.0) | 66.0 (63.0, 71.5) |
| Male | 223 (74.3%) | 74 (74%) |
| Race | ||
| White | 281 (93.7%) | 100 (100%) |
| Black or African-American | 8 (2.7%) | 0 (0%) |
| Asian | 6 (2.0%) | 0 (0%) |
| Other | 5 (1.7%) | 0 (0%) |
| Ethnicity: Hispanic or Latino | 8 (2.7%) | 0 (0%) |
| Smoking | ||
| Past | 202 (67.3%) | 68 (68%) |
| Never | 96 (32.0%) | 32 (32%) |
| Current | 2 (0.7%) | 0 (0%) |
| Diagnostic criteriaa | ||
| Definite IPF | 220 (73.3%) | – |
| Probable IPF | 63 (21.0%) | – |
| Possible IPF | 17 (5.7%) | – |
| Presence of emphysema on CT | 31 (10.3%) | – |
| Supplemental oxygen use at rest | 59 (20.0%)b | – |
| Pulmonary function measures | ||
| FEV1 (L) | 2.2 (1.8, 2.7) | – |
| FEV1 (% predicted) | 77.4 (68.0, 89.1) | – |
| FVC (L) | 2.7 (2.2, 3.2) | – |
| FVC (% predicted) | 69.7 (61.0, 80.2) | – |
| FEV1/FVC ratio | 74.1 (72.8, 89.6) | – |
| DLCO (mL/min/kPa) | 12.0 (8.6, 14.7) | – |
| DLCO (% predicted) | 40.6 (31.7, 49.4) | – |
| CPI | 53.5 (46.6, 60.5) | – |
| Antifibrotic drug use | ||
| Nintedanib | 56 (18.7%) | 0 (0%) |
| Pirfenidone | 106 (35.3%) | 0 (0%) |
| Neither | 138 (46.0%) | 100 (100%) |
Values are median (Q1, Q3) or n (%)
CT computed tomography, CPI composite physiologic index, DLCO diffusing capacity of the lungs for carbon monoxide, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
aDetermined by the investigator according to the 2011 ATS/ERS/JRS/ALAT diagnostic guidelines [15]
bInformation available for 295 patients